Published in Hum Toxicol on October 01, 1982
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene (2006) 2.03
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect (1994) 1.02
Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet (1984) 1.00
N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer (2000) 0.86
The association of the slow acetylator phenotype with bladder cancer. J Med Genet (1983) 0.84
Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis. Onco Targets Ther (2015) 0.75
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
North of England evidence based guidelines development project: methods of guideline development. BMJ (1996) 5.12
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Monitoring adverse reactions to drugs. Br Med J (1977) 4.41
A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry (1990) 3.74
Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) (1985) 2.97
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol (1976) 2.78
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55
Activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet (1979) 2.54
Clinical pharmacology in the National Health Service. J R Soc Med (1978) 2.54
Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol (1992) 2.51
Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project. Qual Health Care (1996) 2.49
Prescribing at the interface between hospitals and general practitioners. BMJ (1992) 2.47
The role of the pharmaceutical industry in postgraduate medical education. Br J Clin Pharmacol (1977) 2.45
Blindness in the Luapula valley. Cent Afr J Med (1967) 2.32
Clinical pharmacology clinics in general practice. Br Med J (1977) 2.28
The discharge of elderly patients from an accident and emergency department: functional changes and risk of readmission. Age Ageing (1990) 2.17
Who should have a PEG? Age Ageing (1993) 2.12
Doctors and the drug makers. Lancet (1984) 2.09
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat Genet (1999) 2.06
Extending the role of the community pharmacist. BMJ (1991) 2.05
Adverse drug reactions in elderly patients. Br J Clin Pharmacol (2004) 2.02
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J (1980) 1.87
Clinical staging in Reye syndrome. Am J Dis Child (1974) 1.84
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Review of yellow cards--1986 and 1987. Br Med J (Clin Res Ed) (1988) 1.81
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
[Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands]. Ned Tijdschr Geneeskd (1995) 1.79
Letter: How do doctors learn about drugs? Lancet (1975) 1.78
Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol (1977) 1.76
Delays to thrombolysis in the treatment of myocardial infarction. J R Coll Physicians Lond (1993) 1.75
Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA (1998) 1.73
Psoriasis and cancer. Br Med J (1979) 1.71
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol (1998) 1.67
Drug information centres: a clinical pharmacologist's view. Proc R Soc Med (1977) 1.66
Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med (1985) 1.65
How can we afford costly medicines? J R Coll Physicians Lond (2000) 1.64
Predicting patients' warfarin requirements. Lancet (1977) 1.61
Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology (1999) 1.58
Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) (1984) 1.57
Compliance with prescribed medicines: a study of elderly patients in the community. J R Coll Gen Pract (1979) 1.49
Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet (1978) 1.49
A survey of phlebotomy among persons with hemochromatosis. Transfusion (1999) 1.49
Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) (1987) 1.46
Low prevalence of hepatitis B in mental handicap hospital. Lancet (1989) 1.45
Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol (1991) 1.44
Geographical differences in adverse drug reaction reporting rates in the Northern Region. Br J Clin Pharmacol (1991) 1.43
HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol Dis (2000) 1.42
Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin (2000) 1.42
Comparison of Nottingham Health Profile (NHP) scores with exercise duration and measures of ischaemia during treadmill exercise testing in patients with coronary artery disease. Eur Heart J (1995) 1.41
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. Br Heart J (1995) 1.40
Spontaneous periodic hypothermia: diencephalic epilepsy. Br Med J (1973) 1.39
ECG for physicians: Brugada syndrome. Resuscitation (2006) 1.39
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med (1986) 1.39
A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med (1999) 1.39
Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ (1993) 1.38
Drug concentration in saliva. Clin Pharmacol Ther (1978) 1.38
Compliance with drug treatment. Br Med J (1979) 1.36
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J (Clin Res Ed) (1985) 1.36
Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed) (1981) 1.35
Pacemaker-induced superior vena cava syndrome: report of four cases and review of the literature. Pacing Clin Electrophysiol (1989) 1.33
Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol (1980) 1.32
Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury (1998) 1.32
A method for obtaining saliva samples from infants and young children. Br J Clin Pharmacol (1978) 1.32
Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (1999) 1.31
Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J Antimicrob Chemother (2000) 1.29
Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med (1998) 1.28
Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol (1979) 1.26
The effects of salicylate on temperature regulation in the rabbit. J Physiol (1970) 1.24
The activity of aryl hydrocarbon hydroxylase in adult human skin. Br J Clin Pharmacol (1979) 1.22
Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol. Eur J Clin Pharmacol (1974) 1.22
Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry (1984) 1.22
The association of age and frailty with paracetamol conjugation in man. Age Ageing (1990) 1.22
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Amiodarone in testis and semen. Lancet (1985) 1.20
Perceptions of pain relief after surgery. BMJ (1990) 1.19
Efficacy and pharmacokinetics of aspirin in post-operative dental pain. Br J Clin Pharmacol (1982) 1.18
Who are the frail elderly? Q J Med (1988) 1.17
Benzodiazepines. Br Med J (1977) 1.15
Family study of antipyrine clearance. Br Med J (Clin Res Ed) (1982) 1.15
Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth (1976) 1.15
Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol (1979) 1.14
Decreased epidermal aryl hydrocarbon hydroxylase and localized pustular psoriasis. Br J Dermatol (1980) 1.14
Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther (1995) 1.14
Transferable pyrogen in human experimental fever. Clin Sci (1971) 1.13
Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther (1990) 1.13